← Back to Search

Virus Vaccine

Yellow Fever Vaccine 17D Immunogenicity for Yellow Fever

Phase 1 & 2

Recruiting

Led By William Messer, MD PhD

Research Sponsored by Oregon Health and Science University

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be between 18 and 65 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up 28 days

Awards & highlights

Study Summary

This trial studies how prior vaccination affects the immune response to the yellow fever vaccine 17D in adults. Participants will provide medical and travel histories, blood samples, and a daily diary of symptoms.

Who is the study for?

Adults aged 20-49 who are in good health and have been previously vaccinated with the yellow fever vaccine (17D) at least 8 years ago. They must be able to follow trial procedures, provide a detailed medical history, and not plan to travel to yellow fever endemic areas during the trial.Check my eligibility

What is being tested?

The study is testing how well adults respond to a re-vaccination of the yellow fever vaccine (17D). It looks at antibody responses and immune cell reactions after getting another dose of the same vaccine they received before.See study design

What are the potential side effects?

Participants may experience symptoms similar to those from their initial vaccination, which can include mild fever, soreness at injection site, or fatigue. A daily diary will help track any side effects for two weeks post-vaccination.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ 28 days

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~28 days

This trial's timeline: 3 weeks for screening, Varies for treatment, and 28 days for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Neutralizing antibody titer boost following vaccination

vaccine viremia following vaccination

Secondary outcome measures

CD4+ immune cell response to vaccination

Other outcome measures

CD8+ immune cell response to vaccination

Memory B cell response to vaccination

cytokine response to vaccination

+1 more

Trial Design

1Treatment groups

Experimental Treatment

Group I: Vaccination armExperimental Treatment1 Intervention

Participants will receive a standard dose of of the yellow fever vaccine 17D (YFVax(r)), 0.5mL suspension in normal saline administered subcutaneously once.

Do I qualify?Apply below to find out

Find a Location

Logistics

Participation is compensated

You will be compensated for participating in this trial.

Who is running the clinical trial?

Oregon Health and Science UniversityLead Sponsor

974 Previous Clinical Trials

7,385,877 Total Patients Enrolled

William Messer, MD PhDPrincipal InvestigatorOregon Health and Science University

Media Library

17D (Virus Vaccine) Clinical Trial Eligibility Overview. Trial Name: NCT05859490 — Phase 1 & 2

Yellow Fever Research Study Groups: Vaccination arm

Yellow Fever Clinical Trial 2023: 17D Highlights & Side Effects. Trial Name: NCT05859490 — Phase 1 & 2

17D (Virus Vaccine) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05859490 — Phase 1 & 2

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

To whom is this clinical experiment accessible?

"Eligible participants for this medical trial are aged between 20 and 49, presenting with yellow fever. 35 patients will be taken into the study in total."

Answered by AI

Does the research encompass individuals of advanced age?

"To qualify for this medical study, applicants must be between the ages of 20 to 49. Additionally, there are 28 trials targeting patients under 18 and 70 specifically designed for those over 65 years old."

Answered by AI

Is enrollment in this research endeavor still open to participants?

"As can be discerned from the clinicaltrials.gov website, this medical trial is currently not recruiting participants. Although this investigation was originally posted on June 1st 2023 and last updated on May 10th 2023, there are still 100 other studies seeking volunteers at present time."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

Immunogenicity of Yellow Fever Vaccine 17D in Adults With Prior 17D Vaccination

William Messer 2023. "Immunogenicity of Yellow Fever Vaccine 17D in Adults With Prior 17D Vaccination". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT05859490.